OmniAb, Inc. OABIW

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
55/100
Moderate

Ranked against 712 peers in Biotechnology

About OmniAb, Inc.

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence … Full OABIW analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.73), suggesting sticky customer base.
  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.79), demonstrating pricing resilience across cycles.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.00), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
50
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where OABIW ranks in Biotechnology

OmniAb, Inc. ranks #179 of 713 scored companies in Biotechnology by moat score — the top 25%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
175 Arcutis Biotherapeutics, Inc. ARQT 55/100 Moderate
176 Immunic, Inc. IMUX 55/100 Moderate
177 Ocean Biomedical, Inc. OCEA 55/100 Moderate
178 OmniAb, Inc. OABI 55/100 Moderate
179 OmniAb, Inc. OABIW 55/100 Moderate
180 Celularity Inc. CELU 55/100 Moderate
181 Celularity Inc. CELUW 55/100 Moderate
182 Fennec Pharmaceuticals Inc. FENC 55/100 Moderate
183 Axsome Therapeutics, Inc. AXSM 54/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How OABIW scores on the Corporate Default defenses

Pricing Power

Score 50 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 56 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 67 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 54 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 53 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 50 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding OABIW's moat

What is OmniAb, Inc.'s moat score?

OmniAb, Inc. (OABIW) scores 55 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #179 of 713 scored companies in Biotechnology, the top 25%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (67/100) and its weakest is Pricing Power (50/100).

How does OmniAb, Inc. compare with other Biotechnology companies?

OmniAb, Inc. ranks #179 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are OmniAb, Inc. (OABI) at 55 just above it and Celularity Inc. (CELU) at 54 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is OmniAb, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for OmniAb, Inc.?

The Corporate Default template measures 6 defenses, and OABIW scores: Pricing Power (50), Cost Advantage (56), Customer Stickiness (67), Capital Efficiency (54), Resilience (53), Scale & Market Position (50). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000